Congenital disorder of glycosylation type Id (CDG Id): phenotypic, biochemical and molecular characterization of a new patient.

Fiche du document

Date

2008

Type de document
Périmètre
Langue
Identifiant
Relations

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1007/s10545-008-0959-x

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/18679822

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pissn/0141-8955[linking], 1573-2665[electronic]

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_C146D923F75D6

Licences

info:eu-repo/semantics/openAccess , Copying allowed only for non-profit organizations , https://serval.unil.ch/disclaimer


Sujets proches En

Glycation

Citer ce document

A. Rimella-Le-Huu et al., « Congenital disorder of glycosylation type Id (CDG Id): phenotypic, biochemical and molecular characterization of a new patient. », Serveur académique Lausannois, ID : 10.1007/s10545-008-0959-x


Métriques


Partage / Export

Résumé 0

Congenital disorders of glycosylation (CDG) are a family of multisystem inherited disorders caused by defects in the biosynthesis of N- or O-glycans. Among the many different subtypes of CDG, the defect of a mannosyltransferase encoded by the human ALG3 gene (chromosome 3q27) is known to cause CDG Id. Six patients with CDG Id have been described in the literature so far. We further delineate the clinical, biochemical, neuroradiological and molecular features of CDG Id by reporting an additional patient bearing a novel missense mutation in the ALG3 gene. All patients with CDG Id display a slowly progressive encephalopathy with microcephaly, severe psychomotor retardation and epileptic seizures. They also share some typical dysmorphic features but they do not present the multisystem involvement observed in other CDG syndromes or any biological marker abnormalities. Unusually marked osteopenia is a feature in some patients and may remain undiagnosed until revealed by pathological fractures. Serum transferrin screening for CDG should be extended to all patients with encephalopathy of unknown origin, even in the absence of multisystem involvement.

document thumbnail

Par les mêmes auteurs

Sur les mêmes sujets

Exporter en